Why is Medinova Diagno. falling/rising?

As of 14-Aug, Medinova Diagnostic Services Ltd is experiencing a decline in its stock price, currently at 42.10, which reflects a decrease of 0.9 or 2.09%. Today's performance indicates that the stock has underperformed its sector by 1.66%. Despite this, Medinova has shown positive returns over various periods, including a 20.91% increase over the past year and a remarkable 191.35% rise over the last five years. However, the company faces challenges such as a negative book value and weak long-term fundamental strength, with net sales growing at an annual rate of only 7.48% and operating profit stagnating at 0% over the last five years. Additionally, the stock's liquidity is adequate, but there has been a significant drop in investor participation, with delivery volume falling by 57.5% against the five-day average. In the broader market context, Medinova's recent performance contrasts with the Sensex, which has shown a slight decline of 0.03% over the past week. While Medinova has outperformed the benchmark in the long term, its current struggles, including a high debt-to-equity ratio and flat results in the latest quarter, contribute to its recent price decline. The stock's risk profile is heightened due to its negative book value and a PEG ratio of 6.8, indicating that while it has delivered strong returns historically, its current valuation may not be sustainable given the underlying financial weaknesses.